Nkarta, Inc. (NKTX)
$2.03-3.33%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $145M
- Beta
- 0.94
- P/E (TTM)
- -1.29
- Short % float
- 6.75%
- Days to cover
- 5.9
- SI change
- +4.4%
- 1W
- -10.57%
- 1M
- -29.51%
- vs SPY 1W
- -10.43%
- vs SPY 1M
- -32.02%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 11
- GROWTH
- 45
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-23.8%
REV YoY-
ROE-39.6%
EPS YoY-
ROA-34.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.29
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.61
P/FCF-
EV/EBITDA-1.80
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E29.68
ALTMAN Z-
CURR RATIO7.98
ND/EBITDA-
BETA0.94
Company news
FAQ
- What is LOPJLB’s current signal on NKTX?
- LOPJLB’s latest quantitative signal on Nkarta, Inc. (NKTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NKTX in?
- Nkarta, Inc. (NKTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Nkarta, Inc. (NKTX) do?
- Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory m…